Amgen is delighted to announce the launch of the

PCSK9 Competitive Grant Program

, which will provide an opportunity for investigators from around the world to compete for individual grants of up to 200,000 USD for novel research proposals that seek to advance the understanding of PCSK9 and atherosclerosis.

The program is global in reach and is open to proposals from established and junior investigators*.

The deadline for applications is Friday, May 11, 2018 (11:59 pm US Pacific Time).

*Junior investigators should be within 5 years of completion of training


Categories: Stem Cells therapy


contract research organization

stem cell therapy